CHMP recommends Erivedge (Roche) for treatment of Basal Cell Carcinoma
Roche has announced that the European Union�s Committee for Medicinal Products for Human Use (CHMP) has recommended conditional approval of Erivedge (vismodegib) for the treatment of adult patients with symptomatic metastatic Basal Cell Carcinoma, or locally advanced Basal Cell Carcinoma inappropriate for surgery or radiotherapy. Conditional approval would make Erivedge the first licensed treatment for patients in Europe with these disfiguring, debilitating and even fatal forms of skin cancer, which are known collectively as advanced Basal Cell Carcinoma.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.